Adverse Event reporting information can be found in footer

Request a Meeting

WHY CHOOSE LUTIGEST®?

Discover how Lutigest® compares with other progesterone formulations

Promotional

Why choose Lutigest®?

Lutigest is an easy-to-use progesterone for effective luteal phase support2,15

  • The findings of this audit offer insights into real-world patient experiences with the progesterone vaginal tablet formulation, Lutigest®. The results suggest overall patient convenience, ease, and comfort with using progesterone vaginal tablets for luteal phase support (LPS). The majority of patients found progesterone vaginal tablets more convenient and comfortable to use compared with progesterone pessaries.15
  • An effervescent vaginal tablet containing 100 mg progesterone1,2
  • Indicated for luteal phase support as part of an assisted reproductive technology (ART) treatment programme1
  • Recommended by NICE, progesterone supplementation for luteal phase support (LPS) after IVF treatment significantly increases pregnancy success rates.3
    • Progesterone is essential for the establishment of an early pregnancy6
    • GnRH analogues used in ART can suppress normal ovarian function6
    • Progesterone supplementation during LPS has become the agent of choice7
  • Compared to intramuscular (IM) progesterone, vaginal administration:
    • Improves compliance8
    • Avoids injection site adverse events such as pain, sterile abscesses or bleeding9
    • Provides similar clinical pregnancy, miscarriage and live birth rates8,9
  • Compared to oral progesterone, vaginal administration of Lutigest® provides greater bioavailability10
  • With regards to pharmacokinetics, vaginal administration allows:
    • Rapid progesterone absorption across the epithelium11
    • High endometrial progesterone concentrations11
    • Rapid progesterone steady states12
  • Compared to IM and oral administration, targeted delivery minimises adverse systemic sedating side effects9,13
  • Compared with vaginal progesterone gel, Lutigest®:
  • Demonstrates similar efficacy5
    • The primary efficacy outcome was ongoing pregnancy (biochemical pregnancy, clinical pregnancy, ongoing pregnancy and live birth rates were also determined)5
    • Produces higher peak concentrations12
    • Achieves steady state serum concentrations of >10 ng/mL more rapidly with less variability12
  • Lutigest® is well-tolerated:14
    • As an effervescent tablet, Lutigest® does not cause messy discharge as is sometimes seen with vaginal suppositories or cream2
    • Absorbs vaginal secretions2
    • Disintegrates into an adhesive powder that adheres to the vaginal epithelium to facilitate sustained release2

Lutigest® resources for healthcare professionals

Including: how to use Lutigest®, clinical and real world evidence, formulations and guidelines

 SEE YOUR RESOURCES
  1. Lutigest. Summary of Product Characteristics. Lutigest 100 mg vaginal tablets Available: https://www.medicines.org.uk/emc/product/3635/smpc#gref (last accessed on 01-September-2023).
  2. Levy T et al. Hum Reprod 1999; 14(3): 606-610.
  3. Fertility. NICE clinical guideline 156. February 2013.
  4. van der Linden M et al. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev 2015; CD009154.
  5. Doody KJ et al. Fertil Steril 2009; 91(4): 1012-17.
  6. Practice Committee of the American Society for Reproductive Medicine. Fertil Steril 2008; 89 (4): 789–792.
  7. Penzias AS. Luteal phase support. Fertil Steril 2002; 77: 318–323.
  8. Mitwally MF et al. Fertil Steril 2010; 93(3): 554-569.
  9. Khan N et al. Fertil Steril 2009; 91: 2445–2450.
  10. Levine H and Watson N. Fertil Steril 2000; 73: 516-521.
  11. Paulson RJ et al. J Clin Endocrinol Metab 2014; 99(11): 4241-4249.
  12. Blake, EJ et al. Fertil Steril 2010; 94: 1296-301.
  13. Warren MP, Shantha S. Int J Fertil Womens Med 1999; 44: 96–103.
  14. Beltsos AN et al. Reprod Health 2014; 11: 78.
  15. Heine P et al. Dove Press 2017; 8: 169-179.

Job Code: UK-LUG-2300004 - Date of preparation: September 2023

cookiepopup

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.